Synthesis and antihypertensive activity of 2,4-dioxoimidazolidin-1-yl and perhydro-2,4-dioxopyrimidin-1-yl ergoline derivatives

Farmaco

Volumn 53, Issue 4, 1998, Pages 293-304

  Mantegani, Sergio ^a   Brambilla, Enzo ^a   Caccia, Carla ^a   Chiodini, Laura ^a   Ruggieri, Daniela ^a   Lamberti, Ernesto ^a   Di Salle, Enrico ^a   Salvati, Patricia ^a  

^a PFIZER INC   (United States)

Author keywords

Antihypertensive activity; Ergolines; Nidation inhibitory activity

Indexed keywords

ERGOLINE DERIVATIVE; HYDANTOIN DERIVATIVE; PROLACTIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DRUG SYNTHESIS; HYPERTENSION; MALE; MOUSE; NIDATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PROLACTIN RELEASE; SPONTANEOUSLY HYPERTENSIVE RAT; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ERGOLINES; FEMALE; MALE; MICE; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031818222     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(98)00023-8     Document Type: Article

References (30)

1. W.T. Rall, in: P.B. Molinoff, W.R. Ruddon (Eds.), The Pharmacological Basis of Therapeutics, 8th ed., MacMillan, New York, 1990, pp. 933-953.
2. Saletu B., Paulus E., Linzmayer L. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-bind placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology. 117:1995;385-395.
3. Fuller W., Clemens J.A., Kornfeld E.C., Snoddy H.D., Smalstig E.B., Bach N.G. Effects of (8β)-8-[(methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats. Life Sci. 24:1979;375-382.
4. Brambilla E., Di Salle E., Briatico G., Mantegani S., Temperilli A. Synthesis and nidation inhibitory activity of a new class of ergoline derivatives. Eur. J. Med. Chem. 24:1989;421-426.
5. Berkowitz A. Dopamine and dopamine receptors as target sites of cardiovascular drug action. Fed. Proc. Fed. Am. Soc. Exp. Biol. 42:1983;3019-3021.
6. Luchsinger A., Velasco M., Urbina A., Morillo J., Romero E., Alvarez R., Pieretti O.H. Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin system in hypertensive patients. J. Clin. Pharmacol. 32:1992;55-60.
7. Alan F., Sved G., Fernstrom J.D. Evidence for a peripheral dopaminergic mechanism in the antihypertensive action of lergotrile. Life Sci. 27:1980;349-354.
8. Yen T., Stamm N.B., Clemens J.A. Pergolide: a potent dopaminergic antihypertensive. Life Sci. 25:1979;209-216.
9. K. Fuxe, S.O. Ogren, L.F. Agnati, K. Andersson, C. Kohler, B. Fredholm, Central monoamine synapses as sites of action of ergot derivatives, in: M. Goldstein, D.B. Calne, A. Lieberman, M.O. Thorner (Eds.), Advances in Biochemistry and Psychopharmacology, vol. 23, Raven Press, New York, 1980, pp. 41-74.
10. 2-serotonin receptor blockade. J. Cardiovasc. Pharmacol. 11(1):1988;54-61.
11. Schliker E., Classen K., Gothert M. Presynaptic serotonin receptors and alpha-adrenoceptors on central serotonergic and noradrenergic neurons of normotensive and spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 11(5):1988;518-528.
12. Eur. Patent Appl. 126 968 (1984) [Chem. Abstr. 102 (1984) 149582y].
13. Salvati P., Bondiolotti G.P., Caccia C., Vaghi F., Bianchi G. Mechanism of the antihypertensive effect of FCE 22716, a new ergoline derivative, in spontaneously hypertensive rat. Pharmacology. 38:1989;78-92.
14. J. March, Advanced Organic Chemistry, 2nd ed., McGraw-Hill, New York, 1985, p. 364.
15. C. Elderfield, Heterocyclic Compounds, vol. 5, Wiley, New York, 1957, p. 256.
16. Holcomb W.F., Hamilton C.S. Derivatives of 4-amino-6-methoxyquinaldine. J. Am. Chem. Soc. 64:1942;1309-1311.
17. D.J. Brown, F. Mason, Chemistry of Heterocyclic Compounds, vol. 16, Wiley, New York, 1962, p. 434.
18. Montzka T., Matiskella J.D., Patyka R.A. 2,2,2-Trichloroethyl chloroformate: a general reagent for demethylation of tertiary methylamines. Tetrahedron Lett. 14:1974;1325-1327.
19. Gribble G.W., Lord P.D., Skotnicki J., Dietz S.E., Eato J.T., Johnson J.R. Reactions of sodium borohydride in acidic media. I. Reduction of indoles and alkylation of aromatic amines, with carboxylic acids J. Am. Chem. Soc. 96:1974;7812-7814.
20. Bernardi L., Camerino B., Patelli B., Redaelli S. Derivati della D-6-methyl-8β-aminomethyl-10α-ergolina. Gazz. Chim. Ital. 94:1964;936-946.
21. Fehr T., Stutz P., Stadler P.A., Hummel R., Salzmann R. Antihypertensiv Wirksame Harnstoffderivate des 8β-Aminomethyl-6-Methyl-Ergolens. Eur. J. Med. Chem. 9:1974;597-601.
22. Hofman A. Über den Curtius'schen Abbau der Isomeren Lysergsäuren und Dihydro-Lysergsäuren. Helv. Chim. Acta. 30:1947;44-51.
23. Semonsky' M., Kucharczyk N. Synthesis of nitrile and amide of D-6-methyl-8-ergolinylacetic acid. Collect. Czech. Chem. Commun. 33:1968;577-601.
24. E. Fluckiger, E. Del Pozo, in: B. Berde, H.O. Schild (Eds.), Handbook of Experimental Pharmacology, vol. 49, Springer, Berlin, 1978, p. 615.
25. 3H]-prazosin to rat brain α-adrenergic receptors. Eur. J. Pharmacol. 55:1979;323-326.
26. 2-adrenergic receptors. Eur. J. Pharmacol. 76:1981;461-464.
27. 3H]-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci. 35:1984;1885-1893.
28. 3H]-Spiroperidol labels dopamine receptors in pituitary and brain. Eur. J. Pharmacol. 46:1977;377-381.
29. 3H]-5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J. Neurochem. 36:1981;220-226.
30. 2 receptor binding sites. Mol. Pharmacol. 21:1981;301-314.